免疫
- 抗肿瘤免疫应答
-
- TLR激动剂 [1]
- Lipopolysaccharides
- Imiquimod
- Resiquimod
- FSL-1
- Motolimod
- Vesatolimod
-
- STING激动剂 [4]
- 3',3'-cGAMP
- 2',3'-cGAMP Sodium Salt
- Alpha-Mangostin
- Vadimezan
- MSA-2
-
- RIG-I激动剂 [5]
- Inarigivir soproxil
- 免疫检查点阻断
-
- Anti-PD-1/PD-L1
- Pembrolizumab
- Nivolumab
- Cemiplimab
- Sintilimab
- Spartalizumab
- Atezolizumab
- Durvalumab
- Avelumab
-
- Anti-CTLA-4
- Ipilimumab
- Tremelimumab
- Zalifrelimab
- Quavonlimab
-
- Anti-LAG-3
- Relatlimab
-
- Anti-CD47
- Magrolimab
- Anti-CD47
-
- Anti-TIM-3
- Sabatolimab
- Cobolimab
-
- Anti-TIGIT
- Tiragolumab
- Vibostolimab
-
- Anti-B7-H3 (CD276)
- Enoblituzumab
- Omburtamab
-
- Anti-BTLA (CD272)
- Icatolimab
- 肿瘤免疫逃逸
-
- TGF-β抑制剂 [7]
- Sulfasalazine
- SB431542
- Galunisertib
- Pirfenidone
- Fresolimumab
-
- PI3K/AKT/mTOR抑制剂 [8]
- Rapamycin
- Everolimus
- Temsirolimus
- Torin 1
- LY294002
- 3-MA
- Miltefosine
- MK-2206 2HCl
-
- JAK/STAT抑制剂 [9]
- Napabucasin
- Curcumin
- Itacitinib
- Ruxolitinib
- Tofacitinib
- Resveratrol
- Baricitinib
- Bosutinib
-
- CCR/CXCR抑制剂
- Reparixin
- SB225002
- Plerixafor
- BX471
- Cenicriviroc
- RS102895
-
- COX2/PGE2抑制剂 [10]
- Vitamin E
- Dexamethasone
- Aspirin
- Resveratrol
- 靶向新生血管 [6]
- Sorafenib
- Sunitinib malate
- Lenalidomide
- Cabozantinib
- Lenvatinib
- Regorafenib
- Axitinib
- Nintedanib
- Apatinib
- Ponatinib
- Erdafitinib
- 免疫共刺激分子
-
- Anti-ICOS (CD278) [11]
- Vopratelimab
- Anti-ICOS / CD278
- Feladilimab
- Alomfilimab
-
- Anti-4-1BB (CD137) [11]
- Urelumab
- Utomilumab
-
- Anti-OX40 (CD134) [11]
- Anti-TNFRSF4 / OX40 / CD134
- Ivuxolimab
- Vonlerizumab
- Telazorlimab
- Tavolixizumab
- Cudarolimab
- Revdofilimab
-
- Anti-TNFRSF5 (CD40) [12]
- Dacetuzumab
- Lucatumumab
- Selicrelumab
- Sotigalimab
- Mitazalimab
- 免疫抑制剂
-
- 细胞毒性分子 [13]
- Cyclophosphamide
- Busulfan
- Cisplatin
- Ifosfamide
- Thiotepa
-
- 免疫蛋白酶体抑制剂
- Bortezomib
- Carfilzomib
- Sotrastaurin
- 免疫增强剂
- 免疫调节剂
- 抗体免疫疗法
- 相关化合物库
- Immunology/Inflammation Compound Library
- Cytokine Inhibitor Library
- Angiogenesis Related compound Library
- JAK/STAT compound library
- NF-κB Signaling Compound Library
- PI3K/Akt Inhibitor Library
- FDA-approved Anticancer Drug Library
- Anti-cancer Compound Library
- Anti-cancer Compound Library-Ⅱ
- Small Molecule Immuno-Oncology Compound Library
参考文献
- [1] Lee S N, et al. Accounts of Chemical Research, 2020, 53(10): 2081-2093.
- [2] Yu H, et al. Signal Transduct Target Ther. 2020 Sep 21;5(1):209.
- [3] Moossavi M, et al. Molecular cancer, 2018, 17(1): 1-13.
- [4] Jiang M, et al. J Hematol Oncol. 2020 Jun 22;13(1):81.
- [5] Bourquin C, et al. Pharmacological research, 2020, 154: 104192.
- [6] Zhang Y, et al. Journal of Leukocyte Biology, 2022, 111(6): 1269-1286.
- [7] Hosseini R, et al. Cancer Gene Therapy, 2023: 1-14.
- [8] Kobayashi Y, et al. Academic Press, 2020, 65: 51-64.
- [9] Owen KL, et al. Cancers. 2019; 11(12):2002.
- [10] Friedmann Angeli JP, et al. Pigment Cell Melanoma Res. 2021 Mar;34(2):268-279
- [11] Anu Sharma, et al. Clinical Immunology (Fifth Edition), 1033-1048.e1 (2019).
- [12] Ara A, et al. Immunotargets Ther. 2018 Jun 28;7:55-61.
- [13] Parlakpinar H, et al. Immunopharmacol Immunotoxicol. 2021 Dec;43(6):651-665.
- [14] Mitra S, et al. Molecules. 2022; 27(2):555.
- [15] Firdaus FZ, et al. Methods Mol Biol. 2022;2412:155-178.
